Simvastatin Versus Ezetimibe

• DOI: 10.1161/01.cir.0000164260.82417.3f
• Publication Date: 2005-05-03T00:16:14Z
• Authors: Ulf Landmesser; Ferdinand Bahlmann; Maja Mueller; Stephan Spiekermann; Nina Kirchhoff; Svenja Schulz; Costantina Manes; Dieter Fischer; Kirsten de Groot; Danilo Fliser; Günter Fauler; Winfried März; Helmut Drexler
• Keywords: Male; Simvastatin; Superoxide Dismutase; Anticholesteremic Agents; Ascorbic Acid; Middle Aged; Ezetimibe; Hematopoietic Stem Cells; Lipids; 3. Good health; Vasodilation; 03 medical and health sciences; 0302 clinical medicine; Radial Artery; Azetidines; Humans; Female; Endothelium, Vascular; Reactive Oxygen Species

Background—

Statins may exert important pleiotropic effects, ie, improve endothelial function, independently of their impact on LDL cholesterol. In humans, however, pleiotropic effects of statins have never been unequivocally demonstrated because prolonged statin treatment always results in reduced LDL cholesterol levels. We therefore tested the hypothesis that similar reductions in LDL cholesterol with simvastatin and ezetimibe, a novel cholesterol absorption inhibitor, result in different effects on endothelial function.

Methods and Results—

Twenty patients with chronic heart failure were randomized to 4 weeks of simvastatin (10 mg/d) or ezetimibe (10 mg/d) treatment. Flow-dependent dilation (FDD) of the radial artery was determined by high-resolution ultrasound before and after intra-arterial vitamin C to determine the portion of FDD inhibited by radicals (ΔFDD-VC). Activity of extracellular superoxide dismutase, a major vascular antioxidant enzyme system, was determined after release from the endothelium by a heparin bolus injection. Endothelial progenitor cells were analyzed with an in vitro assay. Simvastatin and ezetimibe treatment reduced LDL cholesterol to a similar extent (15.6% versus 15.4%; P =NS), whereas changes in mevalonate, the product of HMG-CoA-reductase, differed between groups (Δmevalonate-simvastatin, −1.04±0.62 versus Δmevalonate-ezetimibe, 1.79±0.94 ng/mL; P <0.05 between groups). Importantly, FDD was markedly improved after simvastatin (10.5±0.6% versus 5.1±0.7%; P <0.01) but not after ezetimibe treatment (5.6±0.5% versus 5.8±0.6%; P =NS). ΔFDD-VC was substantially reduced after simvastatin but not after ezetimibe treatment. Extracellular superoxide dismutase activity was increased by >100% ( P <0.05) after simvastatin but not ezetimibe treatment. Simvastatin treatment increased the number of functionally active endothelial progenitor cells, whereas ezetimibe had no effect.

Conclusions—

Four weeks of simvastatin treatment improves endothelial function independently of LDL cholesterol lowering, at least in part by reducing oxidant stress. Simvastatin may thereby exert important pleiotropic effects in humans.